| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1031323914 |
| P356 | DOI | 10.1023/A:1022238706604 |
| P698 | PubMed publication ID | 12708584 |
| P5875 | ResearchGate publication ID | 10792239 |
| P50 | author | Sarah Aldred | Q53323690 |
| Rosemary Waring | Q67776417 | ||
| P2093 | author name string | Michael Fitzgerald | |
| Kieran M. Moore | |||
| P2860 | cites work | Urinary homovanillic acid levels of autistic children | Q50307909 |
| Determination of cysteinesulfinate, hypotaurine and taurine in physiological samples by reversed-phase high-performance liquid chromatography | Q69873249 | ||
| Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache | Q74481419 | ||
| Spinal cord GLT-1 glutamate transporter and blood glutamic acid alterations in motor neuron degeneration (Mnd) mice | Q28592614 | ||
| Autism: review of neurochemical investigation. | Q36605375 | ||
| Dopamine-beta-hydroxylase (DBH) and homovanillic acid (HVA) in autistic children | Q41493551 | ||
| Hippocampal GABA and glutamate transporter immunoreactivity in patients with temporal lobe epilepsy | Q41608153 | ||
| Diagnosis and definition of childhood autism | Q42153662 | ||
| Regional differences in the effects of glutamate uptake inhibitor L-trans-pyrrolidine-2,4-dicarboxylic acid on extracellular amino acids and dopamine in rat brain: an in vivo microdialysis study | Q47691289 | ||
| Optical detection of synaptically induced glutamate transport in hippocampal slices. | Q48257377 | ||
| The expression of the glial glutamate transporter protein EAAT2 in motor neuron disease: an immunohistochemical study. | Q48378456 | ||
| Serotonin and amino acid content in platelets of autistic children | Q50305020 | ||
| Urinary free and conjugated catecholamines and metabolites in autistic children | Q50307518 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | autism | Q38404 |
| autistic child | Q110955678 | ||
| P304 | page(s) | 93-97 | |
| P577 | publication date | 2003-02-01 | |
| P1433 | published in | Journal of Autism and Developmental Disorders | Q6294817 |
| P1476 | title | Plasma amino acid levels in children with autism and their families | |
| P478 | volume | 33 |
| Q37022453 | A randomized controlled pilot trial of oral N-acetylcysteine in children with autism |
| Q28266633 | A retrospective study of memantine in children and adolescents with pervasive developmental disorders |
| Q28477358 | Alteration of plasma glutamate and glutamine levels in children with high-functioning autism |
| Q42575420 | Altered neurotransmitter metabolism in adolescents with high-functioning autism |
| Q52655976 | Altered peripheral amino acid profile indicate a systemic impact of active celiac disease and a possible role of amino acids in disease pathogenesis. |
| Q35625886 | An open-label naturalistic pilot study of acamprosate in youth with autistic disorder |
| Q59263464 | Analysis of amino acids in autism spectrum disorders |
| Q88917826 | Are therapeutic diets an emerging additional choice in autism spectrum disorder management? |
| Q89537222 | Assessments of Amino Acids, Ammonia and Oxidative Stress Among Cohort of Egyptian Autistic Children: Correlations with Electroencephalogram and Disease Severity |
| Q34428337 | Autism and nutrition: the role of the gut-brain axis |
| Q38816381 | Body fluid levels of neuroactive amino acids in autism spectrum disorders: a review of the literature. |
| Q34680116 | Chromatographic methods in the study of autism |
| Q36957597 | Chronomics of autism and suicide |
| Q50306889 | Combined 1H-NMR and 1H-13C HSQC-NMR to improve urinary screening in autism spectrum disorders |
| Q36077054 | Comorbid Analysis of Genes Associated with Autism Spectrum Disorders Reveals Differential Evolutionary Constraints |
| Q27025683 | Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date |
| Q54958844 | Dietary Considerations in Autism Spectrum Disorders: The Potential Role of Protein Digestion and Microbial Putrefaction in the Gut-Brain Axis. |
| Q50310146 | Distinct plasma profile of polar neutral amino acids, leucine, and glutamate in children with Autism Spectrum Disorders |
| Q36727667 | Early pharmacological treatment of autism: a rationale for developmental treatment |
| Q36123660 | Elevated glutamatergic compounds in pregenual anterior cingulate in pediatric autism spectrum disorder demonstrated by 1H MRS and 1H MRSI. |
| Q34073325 | Emerging drugs for the treatment of symptoms associated with autism spectrum disorders |
| Q22337143 | Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. |
| Q37208148 | Family-Based Association Testing of OCD-associated SNPs of SLC1A1 in an autism sample |
| Q35770888 | GABA system dysfunction in autism and related disorders: from synapse to symptoms |
| Q24533852 | Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism |
| Q36713848 | Impact of plasma transaminase levels on the peripheral blood glutamate levels and memory functions in healthy subjects |
| Q89477408 | Importance of Nutrition Intervention in Autistic Patients |
| Q37774095 | Improving the prediction of response to therapy in autism |
| Q34777549 | In vivo 1H-magnetic resonance spectroscopy study of the attentional networks in autism |
| Q26828983 | Increased glutamate and homocysteine and decreased glutamine levels in autism: a review and strategies for future studies of amino acids in autism |
| Q50344999 | Increased markers of oxidative stress in autistic children of the Sultanate of Oman |
| Q38604354 | Is Taurine a Biomarker in Autistic Spectrum Disorder? |
| Q27014201 | Medical treatment overview: traditional and novel psycho-pharmacological and complementary and alternative medications |
| Q90467658 | Metabolomics analysis of children with autism, idiopathic-developmental delays, and Down syndrome |
| Q37183323 | Microsatellite marker in gamma - aminobutyric acid - a receptor beta 3 subunit gene and autism spectrum disorders in Korean trios |
| Q37558748 | Mitochondrial dysfunction in autism |
| Q24630557 | Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis |
| Q39269008 | Neurobiological bases of autism-epilepsy comorbidity: a focus on excitation/inhibition imbalance |
| Q22251205 | New Developments in Autism |
| Q38044266 | New models for considering the role of medication in the treatment and elucidation of the etiology of autism |
| Q48116100 | Non-invasive evaluation of the GABAergic/glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 tesla instrument |
| Q24675057 | Nonvesicular release of glutamate by glial xCT transporters suppresses glutamate receptor clustering in vivo |
| Q35102732 | Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity |
| Q26801276 | Nutritional status of individuals with autism spectrum disorders: do we know enough? |
| Q34105312 | RECENT DEVELOPMENTS IN NEUROPATHOLOGY OF AUTISM SPECTRUM DISORDERS. |
| Q37059666 | Role of NAD(+), Oxidative Stress, and Tryptophan Metabolism in Autism Spectrum Disorders |
| Q35629165 | Single nucleotide polymorphisms predict symptom severity of autism spectrum disorder |
| Q50313366 | Targeting of glycine site on NMDA receptor as a possible new strategy for autism treatment |
| Q27500386 | The Intense World Theory – A Unifying Theory of the Neurobiology of Autism |
| Q92376385 | The Potential of Carnosine in Brain-Related Disorders: A Comprehensive Review of Current Evidence |
| Q28388719 | The dynamics of autism spectrum disorders: how neurotoxic compounds and neurotransmitters interact |
| Q38162501 | The need for a comprehensive molecular characterization of autism spectrum disorders |
| Q37973276 | The potential role of glutamate in the current diabetes epidemic. |
| Q36027303 | The potential role of the antioxidant and detoxification properties of glutathione in autism spectrum disorders: a systematic review and meta-analysis |
| Q26998975 | The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment |
| Q48122460 | The urinary 1 H-NMR metabolomics profile of an italian autistic children population and their unaffected siblings. |
| Q37836872 | Theoretical aspects of autism: biomarkers--a review |
| Q38046662 | mGluR antagonists and GABA agonists as novel pharmacological agents for the treatment of autism spectrum disorders |
Search more.